Thrombocytopenia - Pipeline Review, H1 2016

  • ID: 3753843
  • Report
  • 178 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • Bayer AG
  • Eisai Co., Ltd.
  • Immunomedics, Inc.
  • Neumedicines Inc.
  • PhytoHealth Corporation
  • MORE
Thrombocytopenia - Pipeline Review, H1 2016

Summary

‘Thrombocytopenia - Pipeline Review, H1 2016’, provides an overview of the Thrombocytopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
- The report reviews pipeline therapeutics for Thrombocytopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombocytopenia therapeutics and enlists all their major and minor projects
- The report assesses Thrombocytopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombocytopenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc.
  • Bayer AG
  • Eisai Co., Ltd.
  • Immunomedics, Inc.
  • Neumedicines Inc.
  • PhytoHealth Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Thrombocytopenia Overview

Therapeutics Development

Pipeline Products for Thrombocytopenia - Overview

Pipeline Products for Thrombocytopenia - Comparative Analysis

Thrombocytopenia - Therapeutics under Development by Companies

Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes

Thrombocytopenia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Thrombocytopenia - Products under Development by Companies

Thrombocytopenia - Products under Investigation by Universities/Institutes

Thrombocytopenia - Companies Involved in Therapeutics Development

3SBio Inc.

Amarillo Biosciences, Inc.

Amgen Inc.

Baxalta Incorporated

Bayer AG

BioLineRx, Ltd.

Boehringer Ingelheim GmbH

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Cellerant Therapeutics, Inc.

Eisai Co., Ltd.

Genosco

Hansa Medical AB

Immunomedics, Inc.

Intas Pharmaceuticals Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Myelo Therapeutics GmbH

Neumedicines Inc.

Novartis AG

Pfizer Inc.

PhytoHealth Corporation

Prophylix Pharma AS

Protalex, Inc.

Rigel Pharmaceuticals, Inc.

Shionogi & Co., Ltd.

STATegics, Inc.

UCB S.A.

ViroMed Co., Ltd.

Thrombocytopenia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antibody for Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

avatrombopag - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BBT-059 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BL-8040 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BMS-986004 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CLT-009 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GSK-2285921 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hetrombopag Olamine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

interferon alfa - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lusutrombopag - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-8723 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Myelo-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NMIL-121 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PBF-1509 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PEG-VM501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PHN-013 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PRTX-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism of Action

R&D Progress

romiplostim - Drug Profile

Product Description

Mechanism of Action

R&D Progress

romiplostim biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SKIO-703 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SM-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile

Product Description

Mechanism of Action

R&D Progress

STST-4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

thrombopoietin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Tromplate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TXA-302 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

UCB-7665 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Thrombocytopenia - Recent Pipeline Updates

Thrombocytopenia - Dormant Projects

Thrombocytopenia - Discontinued Products

Thrombocytopenia - Product Development Milestones

Featured News & Press Releases

Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia

Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP

Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP

Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag

Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP

Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia

Sep 28, 2015: Shionogi Receives Marketing and Manufacturing Approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia

Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Sep 04, 2015: Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Thrombocytopenia, H1 2016

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Thrombocytopenia - Pipeline by 3SBio Inc., H1 2016

Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H1 2016

Thrombocytopenia - Pipeline by Amgen Inc., H1 2016

Thrombocytopenia - Pipeline by Baxalta Incorporated, H1 2016

Thrombocytopenia - Pipeline by Bayer AG, H1 2016

Thrombocytopenia - Pipeline by BioLineRx, Ltd., H1 2016

Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H1 2016

Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H1 2016

Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016

Thrombocytopenia - Pipeline by Eisai Co., Ltd., H1 2016

Thrombocytopenia - Pipeline by Genosco, H1 2016

Thrombocytopenia - Pipeline by Hansa Medical AB, H1 2016

Thrombocytopenia - Pipeline by Immunomedics, Inc., H1 2016

Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H1 2016

Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Thrombocytopenia - Pipeline by Merck & Co., Inc., H1 2016

Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016

Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H1 2016

Thrombocytopenia - Pipeline by Neumedicines Inc., H1 2016

Thrombocytopenia - Pipeline by Novartis AG, H1 2016

Thrombocytopenia - Pipeline by Pfizer Inc., H1 2016

Thrombocytopenia - Pipeline by PhytoHealth Corporation, H1 2016

Thrombocytopenia - Pipeline by Prophylix Pharma AS, H1 2016

Thrombocytopenia - Pipeline by Protalex, Inc., H1 2016

Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016

Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H1 2016

Thrombocytopenia - Pipeline by STATegics, Inc., H1 2016

Thrombocytopenia - Pipeline by UCB S.A., H1 2016

Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Thrombocytopenia Therapeutics - Recent Pipeline Updates, H1 2016

Thrombocytopenia - Dormant Projects, H1 2016

Thrombocytopenia - Dormant Projects (Contd..1), H1 2016

Thrombocytopenia - Dormant Projects (Contd..2), H1 2016

Thrombocytopenia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Thrombocytopenia, H1 2016

Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
3SBio Inc.
Amarillo Biosciences, Inc.
Amgen Inc.
Baxalta Incorporated
Bayer AG
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Cellerant Therapeutics, Inc.
Eisai Co., Ltd.
Genosco
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Myelo Therapeutics GmbH
Neumedicines Inc.
Novartis AG
Pfizer Inc.
PhytoHealth Corporation
Prophylix Pharma AS
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
STATegics, Inc.
UCB S.A.
ViroMed Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll